Research Interest 1
For most of the connective tissue diseases, there is currently no effective proven therapy. Development of efficient technologies for the identification and genetic manipulation of the central cell type(s) that are involved in matrix deposition and degradation is a definite step in development of targeted therapeutic modalities in such diseases.
My group focuses on two aspects: 1. Fibrotic diseases where excess deposition of matrix lead to loss of function and 2. Osteoarthritis, where there is increased degradation of matrix leading to failure of cartilage function.
Research Group Membership
- UK-Israel Lectureship Scheme
- Effects of APPA on ochronosis
- The regulation of collagen (I) homotrimer synthesis and its role in musculoskeletal dysfunction
- The role of Syndecan 3 in bone metabolism
- Shedding of the endocytic receptor LRP1 in cartilage: A novel link to the development of osteoarthritis.
- Unravelling the molecular mechanism of CCN2 in glaucoma
- INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN HuR IN MUSCULOSKELETAL DEVELOPMENT AND DISEASE
- Defining the mechanisms by which CTGF protects joints from injury -induced osteoarthritis
- Elucidating the pathways regulating venous identity
- Validating ADAMTS-4/5 as targets for therapy in a naturally occuring mouse model of osteoarthritis
- The role of Cux1 in scarring and fibrosis in scleroderma
- Transcriptional regulation of the Notch and Vegf signalling pathways during angiogenesis and arterio-venous differentiation
- Understanding the regulation of the gene critical for the stuctural and functional activity of Cartilage.
- Engineering ligamentous/ tendon tissue for rotator cuff repair.